Immune clues could guide breast cancer therapy
NCT ID NCT07570524
First seen May 15, 2026 · Last updated May 25, 2026 · Updated 3 times
Summary
This study will analyze tumor and blood samples from 200 women with early triple-negative breast cancer to find immune markers that predict whether immunochemotherapy works well. The goal is to understand why some patients have a complete response while others do not, which could help tailor treatments in the future. Participants will receive standard care, and researchers will compare immune profiles between responders and non-responders.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Eugène Marquis
Rennes, 35000, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.